07.08.2017 • NewsElaine BurridgeKBRammonia

KBR Wins Russian Ammonia Contract

(c) bikeriderlondon/Shutterstock
(c) bikeriderlondon/Shutterstock

Engineering and construction group KBR has been awarded a contract by Dorogobuzh JSC, a subsidiary of Russian fertilizer producer Acron, to provide licensing and basic engineering design services for an ammonia plant revamp. The value of the contract was not disclosed.

KBR will supply its proprietary ammonia technology, which will increase capacity at the plant in Dorogobuzh in Russia’s Smolensk region to 693,000 t/y. The contractor said it will use its KBR Reforming Exchanger System (KRES) together with its True Cold Wall Add-on Converter to achieve a revamp at low cost that will enable Dorogobuzh to produce low-cost ammonia to meet increasing captive demand. A timescale for the project was not provided.

The contract follows an award in May on another Russian ammonia project. Agrochemical group JSC EuroChem Northwest has retained KBR to provide Operator Training Simulator (OTS) and Reliability Based Maintenance (RBM) services for its 1 million t/y plant at Kingisepp, Leningrad Oblast, which is currently under construction. The new facility will use KBR’s Purifier ammonia technology.

Under the terms of the agreement, KBR will deliver OTS and RBM solutions and services on a turnkey basis. These will provide a safe and efficient plant start-up as well as enabling assets to be monitored and reliability strategies to be formulated to continuously improve performance, safety and productivity, KBR said.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.